CareDx (NASDAQ:CDNA) Shares Down 7.9% – What’s Next?

09 Apr 2026, 15:53 by Scott Moore · The Cerbat Gem

Shares of CareDx, Inc. (NASDAQ:CDNA – Get Free Report) fell 7.9% on Thursday . The stock traded as low as $16.49 and last traded at $16.51. 512,981 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 676,247 shares. The stock had previously closed at $17.92.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CDNA. Craig Hallum downgraded shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. BTIG Research increased their price objective on shares of CareDx from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company increased their price objective on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings downgraded shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday, February 27th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $27.33.

Read Our Latest Report on CDNA

CareDx Price Performance

The company has a market capitalization of $831.30 million, a price-to-earnings ratio of -40.53 and a beta of 2.54. The stock’s fifty day simple moving average is $18.50 and its two-hundred day simple moving average is $17.73.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The business had revenue of $108.39 million for the quarter, compared to analyst estimates of $102.76 million. CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.The firm’s revenue for the quarter was up 25.2% on a year-over-year basis. During the same period last year, the company posted $0.18 earnings per share. On average, sell-side analysts predict that CareDx, Inc. will post -0.9 EPS for the current year.

Insider Buying and Selling at CareDx

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares of the company’s stock, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 29,636 shares of company stock worth $625,949 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of CareDx

A number of institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its holdings in shares of CareDx by 1.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock worth $739,000 after purchasing an additional 711 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of CareDx by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock worth $542,000 after purchasing an additional 1,280 shares during the period. Quarry LP acquired a new stake in shares of CareDx in the 4th quarter worth about $25,000. Allspring Global Investments Holdings LLC increased its holdings in shares of CareDx by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock worth $365,000 after acquiring an additional 1,675 shares during the period. Finally, FNY Investment Advisers LLC acquired a new stake in shares of CareDx in the 3rd quarter worth about $31,000.

About CareDx

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.